{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:27:00Z","timestamp":1793158020553,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["02NUK065C"],"award-info":[{"award-number":["02NUK065C"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["03VP00560"],"award-info":[{"award-number":["03VP00560"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001656","name":"Helmholtz-Gemeinschaft","doi-asserted-by":"publisher","award":["HVF-0046"],"award-info":[{"award-number":["HVF-0046"]}],"id":[{"id":"10.13039\/501100001656","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Following resection and standard adjuvant radio- and chemotherapy, approved maintenance therapies for glioblastoma are lacking. Intracavitary radioimmunotherapy (iRIT) with <jats:sup>177<\/jats:sup>Lu-labeled 6A10-Fab fragments targeting tumor-associated carbonic anhydrase XII and injected into the resection cavity offers a novel and promising strategy for improved tumor control.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Three glioblastoma patients underwent tumor resection followed by standard radio- and chemotherapy. These patients with stable disease following completion of standard therapy underwent iRIT on compassionate grounds. After surgical implantation of a subcutaneous injection reservoir with a catheter into the resection cavity, a leakage test with [<jats:sup>99m<\/jats:sup>Tc]Tc-DTPA was performed to rule out leakage into other cerebral compartments. IRIT comprised three consecutive applications over three months for each patient, with 25%, 50%, 25% of the total activity injected. A dosimetry protocol was included with blood sampling and SPECT\/CT of the abdomen to calculate doses for the bone marrow and kidneys as potential organs at risk.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>All three patients presented without relevant leakage after application of [<jats:sup>99m<\/jats:sup>Tc]Tc-DTPA. Two patients underwent three full cycles of iRIT (592\u00a0MBq and 1228\u00a0MBq total activity). One patient showed histologically proven tumor progression after the second cycle (526\u00a0MBq total activity). No relevant therapy-associated toxicities or adverse events were observed. Dosimetry did not reveal absorbed doses above upper dose limits for organs at risk.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In first individual cases, iRIT with [<jats:sup>177<\/jats:sup>Lu]Lu-6A10-Fab appears to be feasible and safe, without therapy-related side effects. A confirmatory multicenter phase-I-trial was recently opened and is currently recruiting.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13550-023-01029-7","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T13:02:56Z","timestamp":1693832576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["First clinical experience with fractionated intracavitary radioimmunotherapy using [177Lu]Lu-6A10-Fab fragments in patients with glioblastoma: a pilot study"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3746-9393","authenticated-orcid":false,"given":"Wolfgang","family":"Roll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"M\u00fcther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"B\u00f6ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Delker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Warneke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz-Josef","family":"Gildehaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sch\u00e4fers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Stummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Zeidler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00fcrgen","family":"Reulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Stegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"key":"1029_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0360-3016(92)91021-E","volume":"24","author":"LE Gaspar","year":"1992","unstructured":"Gaspar LE, Fisher BJ, Macdonald DR, LeBer DV, Halperin EC, Schold SCJ, et al. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys. 1992;24:55\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1029_CR2","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3171\/2014.12.JNS142168","volume":"123","author":"H-J Reulen","year":"2015","unstructured":"Reulen H-J, Poepperl G, Goetz C, Gildehaus FJ, Schmidt M, Tatsch K, et al. Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy. J Neurosurg. 2015;123:760\u201370.","journal-title":"J Neurosurg"},{"key":"1029_CR3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3171\/2010.2.JNS091211","volume":"113","author":"L Li","year":"2010","unstructured":"Li L, Quang TS, Gracely EJ, Kim JH, Emrich JG, Yaeger TE, et al. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J Neurosurg. 2010;113:192\u20138.","journal-title":"J Neurosurg"},{"key":"1029_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.nucmedbio.2018.02.004","volume":"60","author":"L Fiedler","year":"2018","unstructured":"Fiedler L, Kellner M, Gosewisch A, Oos R, B\u00f6ning G, Lindner S, et al. Evaluation of (177)Lu[Lu]-CHX-A\u2033-DTPA-6A10 Fab as a radioimmunotherapy agent targeting carbonic anhydrase XII. Nucl Med Biol. 2018;60:55\u201362.","journal-title":"Nucl Med Biol"},{"key":"1029_CR5","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00701-019-03882-9","volume":"161","author":"H-J Reulen","year":"2019","unstructured":"Reulen H-J, Suero Molina E, Zeidler R, Gildehaus FJ, B\u00f6ning G, Gosewisch A, et al. Intracavitary radioimmunotherapy of high-grade gliomas: present status and future developments. Acta Neurochir (Wien). 2019;161:1109\u201324.","journal-title":"Acta Neurochir (Wien)"},{"key":"1029_CR6","first-page":"220","volume":"48","author":"M Bartolomei","year":"2004","unstructured":"Bartolomei M, Mazzetta C, Handkiewicz-Junak D, Bodei L, Rocca P, Grana C, et al. Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide. Q J Nucl Med Mol Imaging. 2004;48:220\u20138.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"1029_CR7","doi-asserted-by":"publisher","first-page":"6494","DOI":"10.1158\/0008-5472.CAN-13-1110","volume":"73","author":"G Gondi","year":"2013","unstructured":"Gondi G, Mysliwietz J, Hulikova A, Jen JP, Swietach P, Kremmer E, et al. Antitumor efficacy of a monoclonal antibody that inhibits the activity of cancer-associated carbonic anhydrase XII. Cancer Res. 2013;73:6494\u2013503.","journal-title":"Cancer Res"},{"key":"1029_CR8","first-page":"1042","volume":"46","author":"G Akabani","year":"2005","unstructured":"Akabani G, Reardon DA, Coleman RE, Wong TZ, Metzler SD, Bowsher JE, et al. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med. 2005;46:1042\u201351.","journal-title":"J Nucl Med"},{"key":"1029_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","volume":"43","author":"A Delker","year":"2016","unstructured":"Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, et al. Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:42\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1029_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/JCO.2005.03.4082","volume":"24","author":"DA Reardon","year":"2006","unstructured":"Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, et al. Salvage radioimmunotherapy with murine iodine-131\u2013labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol. 2006;24:115\u201322.","journal-title":"J Clin Oncol"},{"key":"1029_CR11","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/ijc.2910610608","volume":"61","author":"IM Hennig","year":"1995","unstructured":"Hennig IM, Laissue JA, Horisberger U, Reubi JC. Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J cancer. 1995;61:786\u201392.","journal-title":"Int J cancer"},{"key":"1029_CR12","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1215\/S1152851705000025","volume":"7","author":"MA Proescholdt","year":"2005","unstructured":"Proescholdt MA, Mayer C, Kubitza M, Schubert T, Liao S-Y, Stanbridge EJ, et al. Expression of hypoxia-inducible carbonic anhydrases in brain tumors. Neuro Oncol. 2005;7:465\u201375.","journal-title":"Neuro Oncol"},{"key":"1029_CR13","doi-asserted-by":"publisher","first-page":"103395","DOI":"10.1016\/j.critrevonc.2021.103395","volume":"163","author":"Y Li","year":"2021","unstructured":"Li Y, Marcu LG, Hull A, Bezak E. Radioimmunotherapy of glioblastoma multiforme: current status and future prospects. Crit Rev Oncol Hematol. 2021;163:103395.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1029_CR14","doi-asserted-by":"publisher","first-page":"113951","DOI":"10.1016\/j.addr.2021.113951","volume":"177","author":"C Bastiancich","year":"2021","unstructured":"Bastiancich C, Malfanti A, Pr\u00e9at V, Rahman R. Rationally designed drug delivery systems for the local treatment of resected glioblastoma. Adv Drug Deliv Rev. 2021;177:113951.","journal-title":"Adv Drug Deliv Rev"},{"key":"1029_CR15","doi-asserted-by":"crossref","unstructured":"Liu Z, Zhou J, Yang X, Liu Y, Zou C, Lv W, et al. Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma. Mol Cancer. 2023;22.","DOI":"10.1186\/s12943-022-01711-9"},{"key":"1029_CR16","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-001-0717-x","volume":"29","author":"T Schumacher","year":"2002","unstructured":"Schumacher T, Hofer S, Eichhorn K, Wasner M, Zimmerer S, Freitag P, et al. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med Mol Imaging. 2002;29:486\u201393.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1029_CR17","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s00259-018-4225-7","volume":"46","author":"L Kr\u00f3licki","year":"2019","unstructured":"Kr\u00f3licki L, Bruchertseifer F, Kunikowska J, Koziara H, Kr\u00f3licki B, Jakuci\u0144ski M, et al. Safety and efficacy of targeted alpha therapy with 213 Bi-DOTA-substance P in recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2019;46:614\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1029_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11060-018-03005-x","volume":"141","author":"O Grauer","year":"2019","unstructured":"Grauer O, Jaber M, Hess K, Weckesser M, Schwindt W, Maring S, et al. Combined intracavitary thermotherapy with iron oxide nanoparticles and radiotherapy as local treatment modality in recurrent glioblastoma patients. J Neurooncol. 2019;141:83\u201394.","journal-title":"J Neurooncol"},{"key":"1029_CR19","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S0360-3016(99)00500-3","volume":"46","author":"G Akabani","year":"2000","unstructured":"Akabani G, Cokgor I, Coleman RE, Gonz\u00e1lez Trotter D, Wong TZ, Friedman HS, et al. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int J Radiat Oncol Biol Phys. 2000;46:947\u201358.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1029_CR20","first-page":"912","volume":"47","author":"DA Reardon","year":"2006","unstructured":"Reardon DA, Quinn JA, Akabani G, Coleman RE, Friedman AH, Friedman HS, et al. Novel human IgG2b\/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: Phase I trial results. J Nucl Med. 2006;47:912\u20138.","journal-title":"J Nucl Med"},{"key":"1029_CR21","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.2967\/jnumed.114.149690","volume":"56","author":"CT Mendler","year":"2015","unstructured":"Mendler CT, Gehring T, Wester HJ, Schwaiger M, Skerra A. 89Zr-labeled versus 124I-labeled \u03b1HER2 fab with optimized plasma half-life for high-contrast tumor imaging in vivo. J Nucl Med. 2015;56:1112\u20138.","journal-title":"J Nucl Med"},{"key":"1029_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","volume":"21","author":"B Emami","year":"1991","unstructured":"Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109\u201322.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1029_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/1748-717X-6-141","volume":"6","author":"M Niewald","year":"2011","unstructured":"Niewald M, Berdel C, Fleckenstein J, Licht N, Ketter R, R\u00fcbe C. Toxicity after radiochemotherapy for glioblastoma using temozolomide: a retrospective evaluation. Radiat Oncol. 2011;6:141.","journal-title":"Radiat Oncol"},{"key":"1029_CR24","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1215\/15228517-2007-053","volume":"10","author":"DA Reardon","year":"2008","unstructured":"Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE 2nd, et al. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol. 2008;10:182\u20139.","journal-title":"Neuro Oncol"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-023-01029-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-023-01029-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-023-01029-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T03:50:27Z","timestamp":1700538627000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-023-01029-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1029"],"URL":"https:\/\/doi.org\/10.1186\/s13550-023-01029-7","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]},"assertion":[{"value":"25 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained for retrospective analysis (Ref: 2023-411-f-S; Ethik-Kommission Westfalen Lippe). Informed consent was obtained from all three patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}